The Committee to Study HIV Transmission Through Blood and Blood Products made the following recommendation to the Department of Health and Human Services in the United States: "Where uncertainties or countervailing public health concerns preclude completely eliminating potential risks, the FDA should encourage, and where necessary require, the blood industry to implement partial solutions that have little risk of causing harm."